



Multimeric Biotherapeutics, Inc.
("MultimericBio")
"Unlocking the potential of the TNF SuperFamily Ligands"

Multimeric Biotherapeutics selected to present at 2010 BIO International Convention

April 12, 2010, San Diego, CA – Multimeric Biotherapeutics, Inc. has been invited to present at the 2010 BIO International Convention. Dr. Richard Kornbluth, President and Chief Scientific Officer, will describe the company's groundbreaking technology in a session entitled "Enhanced Responses: Adjuvants and Immunomodulators for New Vaccines" to be held on Monday, May 3, 2010, 4:00 – 5:30 PM in Room S403B, McCormick Place Convention Center in Chicago. The session is sponsored by Sanofi-Pasteur, the vaccine business of Sanofi-Aventis.

The presentation will explain MultimericBio's patented technology for expressing CD40 ligand (CD40L) and other TNF SuperFamily ligands as highly active many-trimer multimers (UltraLigands™). Data will be presented to show the effectiveness of UltraCD40L™ as a immunological stimulant or adjuvant for vaccines against cancer and chronic viral infections such as HIV.

Expected to drawn over 16,000 attendees, the BIO Convention is the world's largest meeting of Pharma and Biotech companies and investors. Outside of its presentation slot, MultimericBio expects to use the remainder of the four day conference meeting with potential development partners and investors.

For further details, visit the company's website: www.multimericbio.com

About Multimeric Biotherapeutics, Inc.

Multimeric Biotherapeutics, Inc. is an early-stage biotech company focused on applying CD40L and other TNF SuperFamily ligands for the prevention and treatment of disease. It uses its novel technology to create next-generation vaccines and tumor immunotherapies. More information is available at www.multimericbio.com . Contact us at info@multimericbio.com